Toxic encephalopathy after exposure to azacitidine

Leukemia and Lymphoma

Volumn 56, Issue 5, 2015, Pages 1538-1539

  Watanabe, Ken ^a   Doki, Noriko ^a   Miura, Yoshiharu ^a   Hagino, Takeshi ^a   Kurosawa, Shuhei ^a   Hino, Yutaro ^a   Shingai, Naoki ^a   Yoshioka, Kosuke ^a   Ishida, Shinya ^a   Igarashi, Aiko ^a   Najima, Yuho ^a   Kobayashi, Takeshi ^a   Kakihana, Kazuhiko ^a   Sakamaki, Hisashi ^a   Ohashi, Kazuteru ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; AZACITIDINE; CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN; CD38 ANTIGEN; CYTARABINE; GRANISETRON; HEMOGLOBIN; HLA DR ANTIGEN; LACTATE DEHYDROGENASE; MICROSOMAL AMINOPEPTIDASE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AIRWAY PRESSURE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; BRAIN TOXICITY; CASE REPORT; CLINICAL EXAMINATION; CONSCIOUSNESS DISORDER; CYTOGENETICS; DELTA RHYTHM; DIABETES MELLITUS; DISORIENTATION; DRUG ERUPTION; DRUG EXPOSURE; ELECTROENCEPHALOGRAPHY; GLASGOW COMA SCALE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LEUKOCYTE COUNT; LEUKOCYTOSIS; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTE; MONOCYTE MACROPHAGE PRECURSOR CELL; MYELOBLAST; NAUSEA; NEUROLOGIC EXAMINATION; NEUTROPHIL COUNT; PAROXYSMAL ATRIAL FIBRILLATION; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; SPLENOMEGALY; THETA RHYTHM; THROMBOCYTE COUNT; NEUROTOXICITY SYNDROMES;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES;

EID: 84932170760     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.964701     Document Type: Letter

References (11)

1. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
2. Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013; 98: 1067-1072.
3. Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratif cation, and management. Am J Hematol 2014;89:97-108.
4. Keating GM. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs 2012;72:1111-1136.
5. Kaminskas E, Farrell AT, Wang YC, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005;10:176-182.
6. Von Hoff DD, Slavik M, Muggia FM. 5-Azacytidine.Anewanticancer drug with Effectiveness in acute myelogenous leukemia. Ann Intern Med 1976;85:237-245.
7. Vardiman JW, Tiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classif cation of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-951.
8. Kim Y, Kim JW. Toxic encephalopathy. Saf Health Work 2012;3: 243-256.
9. Ruha AM, Levine M. Central nervous system toxicity. Emerg Med Clin North Am 2014;32:205-221.
10. Uchida T, Ogawa Y, Kobayashi Y, et al. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci 2011;102:1680-1686.
11. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11: 3604-3608.